Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 2Solid Tumor 1Solid Advanced Tumor 1Neoplasms 1Carcinoma 1Brain Neoplasms 1

Interventions

Carboplatin 99Pemetrexed 71pembrolizumab 69Cisplatin 60Paclitaxel 54Docetaxel 45Gemcitabine 37Erlotinib Hydrochloride 24Nivolumab 23osimertinib 17Bevacizumab 17durvalumab 14Cetuximab 13130-nm albumin-bound paclitaxel 13Gefitinib 11Etoposide 11Drug Therapy 11Ipilimumab 9Injections 9Albumin-Bound Paclitaxel 9Vinorelbine 8Radiotherapy 8motexafin gadolinium 7capmatinib 7atezolizumab 7epacadostat 6Taxes 6Cyclophosphamide 6vandetanib 5entinostat 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Lung Neoplasms × ensartinib × Clear all
NCT03608007 2020-01-09

X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement

Betta Pharmaceuticals Co., Ltd.

Phase 2 Unknown
69 enrolled
Thoracic

Lung Neoplasms

NCT03536481 2019-07-24

Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers

Betta Pharmaceuticals Co., Ltd.

Phase 1 Completed
74 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡